{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.answeringMemberConstituency=Battersea&answer.answeringMember.label=Biography+information+for+Jane+Ellison&max-answer.dateOfAnswer=2014-06-11", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?answer.answeringMemberConstituency=Battersea&answer.answeringMember.label=Biography+information+for+Jane+Ellison&max-answer.dateOfAnswer=2014-06-11", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.answeringMemberConstituency=Battersea&_metadata=all&answer.answeringMember.label=Biography+information+for+Jane+Ellison&max-answer.dateOfAnswer=2014-06-11", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&answer.answeringMemberConstituency=Battersea&answer.answeringMember.label=Biography+information+for+Jane+Ellison&max-answer.dateOfAnswer=2014-06-11", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.answeringMemberConstituency=Battersea&answer.answeringMember.label=Biography+information+for+Jane+Ellison&max-answer.dateOfAnswer=2014-06-11", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.answeringMemberConstituency=Battersea&answer.answeringMember.label=Biography+information+for+Jane+Ellison&max-answer.dateOfAnswer=2014-06-11", "items" : [{"_about" : "http://data.parliament.uk/resources/58392", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/58392/answer", "answerText" : {"_value" : "<p>The Government has noted the report and is currently considering how to respond to the recommendations<strong>.<\/strong><\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
        }
        , "answeringMemberConstituency" : {"_value" : "Battersea"}
        , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        , "dateOfAnswer" : {"_value" : "2014-06-10", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-06-10T15:23:48.5303857Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-06-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Sunbeds"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, whether the Government plans to respond to the recommendations set out in the report of the All Party Parliamentary Group on Skin on sunbed regulation published in 2014.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4036", "label" : {"_value" : "Biography information for Luciana Berger"}
      }
      , "tablingMemberConstituency" : {"_value" : "Liverpool, Wavertree"}
      , "tablingMemberPrinted" : [{"_value" : "Luciana Berger"}
      ], "uin" : "199381"}
    , {"_about" : "http://data.parliament.uk/resources/58393", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/58393/answer", "answerText" : {"_value" : "<p>We have not made any estimate of extending the human papillomavirus (HPV) vaccination programme to include boys aged 12 and 13 years, as the Joint Committee on Vaccination and Immunisation has not yet completed its consideration of whether HPV vaccine should be offered to males.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
        }
        , "answeringMemberConstituency" : {"_value" : "Battersea"}
        , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        , "dateOfAnswer" : {"_value" : "2014-06-10", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-06-10T14:44:56.5091119Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-06-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Human Papillomavirus"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what estimate he has made of the potential cost of extending the human papilloma virus vaccination programme to include all boys aged 12 and 13 years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4036", "label" : {"_value" : "Biography information for Luciana Berger"}
      }
      , "tablingMemberConstituency" : {"_value" : "Liverpool, Wavertree"}
      , "tablingMemberPrinted" : [{"_value" : "Luciana Berger"}
      ], "uin" : "199382"}
    , {"_about" : "http://data.parliament.uk/resources/58394", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/58394/answer", "answerText" : {"_value" : "<p>Research in the evidence around the effectiveness of alcohol harm reduction communications and related campaigns suggests that labelling and point of sale information can have an impact on consumption, in conjunction with broader campaigns to raise consumer awareness and education on the health risks linked to alcohol consumption.<\/p><p><strong> <\/strong><\/p><p>As part of the Public Health Responsibility Deal, alcohol retailers and producers have committed to putting an agreed warning or a pregnancy warning logo on 80% of labels on bottles and cans by the end of 2013. An independent market survey is underway to measure compliance. This level of coverage should allow the majority of consumers to see the pregnancy warning and logo.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
        }
        , "answeringMemberConstituency" : {"_value" : "Battersea"}
        , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        , "dateOfAnswer" : {"_value" : "2014-06-10", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-06-10T15:29:37.6664142Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-06-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Pregnancy: Alcoholic Drinks"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what the Government's assessment is of the effectiveness of warning labels on alcoholic beverages regarding drinking during pregnancy; and what assessment he has made of the potential benefits of making such labels mandatory.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4036", "label" : {"_value" : "Biography information for Luciana Berger"}
      }
      , "tablingMemberConstituency" : {"_value" : "Liverpool, Wavertree"}
      , "tablingMemberPrinted" : [{"_value" : "Luciana Berger"}
      ], "uin" : "199389"}
    , {"_about" : "http://data.parliament.uk/resources/58513", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/58513/answer", "answerText" : {"_value" : "<p>The NHS England Specialised Commissioning team introduced nationally developed service specifications for a range of areas, including prostate cancer, during 2013-14. Prior to 2013, prostate cancer was routinely commissioned by primary care trusts, and as such an assessment of the changes in the level of access to prostate cancer treatments since 2010 is not technically feasible.<\/p><p> <\/p><p>Routinely commissioned treatments for prostate cancer are: (i) radical prostatectomy; (ii) radical external beam radiotherapy; and (iii) radical brachytherapy. In addition, NHS England routinely commissions systemic treatments for prostate cancer, including hormone therapy and chemotherapy.<\/p><p> <\/p><p>The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance which recommends docetaxel (Taxotere) for hormone-refractory prostate cancer and abiraterone (Zytiga), in combination with prednisolone or prednisone, for castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen. NICE is also currently developing technology appraisal guidance on a number of other drugs for prostate cancer.<\/p><p> <\/p><p>National Health Service commissioners are legally required by regulations to fund those treatments recommended by NICE in its technology appraisal guidance.<\/p><p> <\/p><p>Five-year survival rates improved from around 42% in the late 1980s to 79.7% in 2007 (currently 80.2% according to data for 2006-2010 published in October 2012) due in part to the effects of increased Prostate Specific Antigen testing and earlier detection. However, survival rates in England are still lagging behind comparable countries in Europe.<\/p><p> <\/p><p>Cancer Research UK has estimated that men with advanced, incurable prostate cancer treated in trials or under drug access schemes at the Royal Marsden Hospital survived on average 41 months, compared to between 13 and 16 months 10 years ago.<\/p><p> <\/p><p>The Government's Mandate to NHS England sets out an ambition to make England one of the most successful countries in Europe at preventing premature deaths from all cancers, including prostate cancer. Cancer indicators in the NHS Outcomes Framework and the Public Health Outcomes Framework will help NHS England to assess progress in improving cancer survival and mortality for men with prostate cancer.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
        }
        , "answeringMemberConstituency" : {"_value" : "Battersea"}
        , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        , "dateOfAnswer" : {"_value" : "2014-06-10", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "199303"}
        , {"_value" : "199304"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-06-10T15:28:08.1244279Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-06-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Prostate Cancer"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what assessment he has made of the changes in the level of access to prostate cancer treatments since 2010.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4022", "label" : {"_value" : "Biography information for Oliver Colvile"}
      }
      , "tablingMemberConstituency" : {"_value" : "Plymouth, Sutton and Devonport"}
      , "tablingMemberPrinted" : [{"_value" : "Oliver Colvile"}
      ], "uin" : "199302"}
    , {"_about" : "http://data.parliament.uk/resources/58515", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/58515/answer", "answerText" : {"_value" : "<p>The NHS England Specialised Commissioning team introduced nationally developed service specifications for a range of areas, including prostate cancer, during 2013-14. Prior to 2013, prostate cancer was routinely commissioned by primary care trusts, and as such an assessment of the changes in the level of access to prostate cancer treatments since 2010 is not technically feasible.<\/p><p> <\/p><p>Routinely commissioned treatments for prostate cancer are: (i) radical prostatectomy; (ii) radical external beam radiotherapy; and (iii) radical brachytherapy. In addition, NHS England routinely commissions systemic treatments for prostate cancer, including hormone therapy and chemotherapy.<\/p><p> <\/p><p>The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance which recommends docetaxel (Taxotere) for hormone-refractory prostate cancer and abiraterone (Zytiga), in combination with prednisolone or prednisone, for castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen. NICE is also currently developing technology appraisal guidance on a number of other drugs for prostate cancer.<\/p><p> <\/p><p>National Health Service commissioners are legally required by regulations to fund those treatments recommended by NICE in its technology appraisal guidance.<\/p><p> <\/p><p>Five-year survival rates improved from around 42% in the late 1980s to 79.7% in 2007 (currently 80.2% according to data for 2006-2010 published in October 2012) due in part to the effects of increased Prostate Specific Antigen testing and earlier detection. However, survival rates in England are still lagging behind comparable countries in Europe.<\/p><p> <\/p><p>Cancer Research UK has estimated that men with advanced, incurable prostate cancer treated in trials or under drug access schemes at the Royal Marsden Hospital survived on average 41 months, compared to between 13 and 16 months 10 years ago.<\/p><p> <\/p><p>The Government's Mandate to NHS England sets out an ambition to make England one of the most successful countries in Europe at preventing premature deaths from all cancers, including prostate cancer. Cancer indicators in the NHS Outcomes Framework and the Public Health Outcomes Framework will help NHS England to assess progress in improving cancer survival and mortality for men with prostate cancer.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
        }
        , "answeringMemberConstituency" : {"_value" : "Battersea"}
        , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        , "dateOfAnswer" : {"_value" : "2014-06-10", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "199302"}
        , {"_value" : "199304"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-06-10T15:28:10.7493701Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-06-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Prostate Cancer"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what treatments for prostate cancer are routinely funded by NHS England.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4022", "label" : {"_value" : "Biography information for Oliver Colvile"}
      }
      , "tablingMemberConstituency" : {"_value" : "Plymouth, Sutton and Devonport"}
      , "tablingMemberPrinted" : [{"_value" : "Oliver Colvile"}
      ], "uin" : "199303"}
    , {"_about" : "http://data.parliament.uk/resources/58516", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/58516/answer", "answerText" : {"_value" : "<p>The NHS England Specialised Commissioning team introduced nationally developed service specifications for a range of areas, including prostate cancer, during 2013-14. Prior to 2013, prostate cancer was routinely commissioned by primary care trusts, and as such an assessment of the changes in the level of access to prostate cancer treatments since 2010 is not technically feasible.<\/p><p> <\/p><p>Routinely commissioned treatments for prostate cancer are: (i) radical prostatectomy; (ii) radical external beam radiotherapy; and (iii) radical brachytherapy. In addition, NHS England routinely commissions systemic treatments for prostate cancer, including hormone therapy and chemotherapy.<\/p><p> <\/p><p>The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance which recommends docetaxel (Taxotere) for hormone-refractory prostate cancer and abiraterone (Zytiga), in combination with prednisolone or prednisone, for castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen. NICE is also currently developing technology appraisal guidance on a number of other drugs for prostate cancer.<\/p><p> <\/p><p>National Health Service commissioners are legally required by regulations to fund those treatments recommended by NICE in its technology appraisal guidance.<\/p><p> <\/p><p>Five-year survival rates improved from around 42% in the late 1980s to 79.7% in 2007 (currently 80.2% according to data for 2006-2010 published in October 2012) due in part to the effects of increased Prostate Specific Antigen testing and earlier detection. However, survival rates in England are still lagging behind comparable countries in Europe.<\/p><p> <\/p><p>Cancer Research UK has estimated that men with advanced, incurable prostate cancer treated in trials or under drug access schemes at the Royal Marsden Hospital survived on average 41 months, compared to between 13 and 16 months 10 years ago.<\/p><p> <\/p><p>The Government's Mandate to NHS England sets out an ambition to make England one of the most successful countries in Europe at preventing premature deaths from all cancers, including prostate cancer. Cancer indicators in the NHS Outcomes Framework and the Public Health Outcomes Framework will help NHS England to assess progress in improving cancer survival and mortality for men with prostate cancer.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
        }
        , "answeringMemberConstituency" : {"_value" : "Battersea"}
        , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        , "dateOfAnswer" : {"_value" : "2014-06-10", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "199302"}
        , {"_value" : "199303"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-06-10T15:28:11.1243643Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-06-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Prostate Cancer"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what assessment his Department has made of outcomes for men with advanced prostate cancer.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4022", "label" : {"_value" : "Biography information for Oliver Colvile"}
      }
      , "tablingMemberConstituency" : {"_value" : "Plymouth, Sutton and Devonport"}
      , "tablingMemberPrinted" : [{"_value" : "Oliver Colvile"}
      ], "uin" : "199304"}
    , {"_about" : "http://data.parliament.uk/resources/57636", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/57636/answer", "answerText" : {"_value" : "<p>The Department does not collect National Health Service expenditure on treating individual cancers or other diagnoses. It does collect reference costs, which are the average unit costs to NHS trusts and NHS foundation trusts of providing defined services in a given year to NHS patients.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
        }
        , "answeringMemberConstituency" : {"_value" : "Battersea"}
        , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        , "dateOfAnswer" : {"_value" : "2014-06-11", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-06-11T15:48:30.6285694Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-06-04", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, how much the NHS has spent on treating (a) anal cancer, (b) penile cancer, (c) cervical cancer, (d) vaginal cancer, (e) vulval cancer, (f) oropharyngeal cancer, (g) genital warts and (h) recurrent respiratory papillomatosis in the last year.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1390", "label" : {"_value" : "Biography information for Mr John Baron"}
      }
      , "tablingMemberConstituency" : {"_value" : "Basildon and Billericay"}
      , "tablingMemberPrinted" : [{"_value" : "Mr John Baron"}
      ], "uin" : "198632"}
    , {"_about" : "http://data.parliament.uk/resources/57696", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/57696/answer", "answerText" : {"_value" : "<p>This information is not held by the Department.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
        }
        , "answeringMemberConstituency" : {"_value" : "Battersea"}
        , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        , "dateOfAnswer" : {"_value" : "2014-06-11", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "198560"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-06-11T15:45:44.0823382Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-06-04", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Out of Area Treatment: Wales"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, how many patients resident in England but receiving health care in Wales have requested that their treatment be delivered in England in the last year.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1545", "label" : {"_value" : "Biography information for David T C Davies"}
      }
      , "tablingMemberConstituency" : {"_value" : "Monmouth"}
      , "tablingMemberPrinted" : [{"_value" : "David T. C. Davies"}
      ], "uin" : "198553"}
    , {"_about" : "http://data.parliament.uk/resources/57697", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/57697/answer", "answerText" : {"_value" : "<p>This information is not held by the Department.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
        }
        , "answeringMemberConstituency" : {"_value" : "Battersea"}
        , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        , "dateOfAnswer" : {"_value" : "2014-06-11", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "198553"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-06-11T15:45:44.0041691Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-06-04", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Out of Area Treatment: Wales"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, how many patients resident in England have requested that their treatment be delivered in Wales in the last three years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1545", "label" : {"_value" : "Biography information for David T C Davies"}
      }
      , "tablingMemberConstituency" : {"_value" : "Monmouth"}
      , "tablingMemberPrinted" : [{"_value" : "David T. C. Davies"}
      ], "uin" : "198560"}
    , {"_about" : "http://data.parliament.uk/resources/57701", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/57701/answer", "answerText" : {"_value" : "<p>An updated guideline, <em>The Care of Women Requesting Induced Abortion, <\/em>was published in 2011. The Royal College of Obstetricians and Gynaecologists is maintaining a watching brief on the needto review recommendations in the light of new research evidence.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
        }
        , "answeringMemberConstituency" : {"_value" : "Battersea"}
        , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        , "attachment" : {"_about" : "http://data.parliament.uk/resources/57701/answer/attachment/1", "fileName" : {"_value" : "Hansard Extract.docx"}
          , "title" : "Hansard Extract"}
        , "dateOfAnswer" : {"_value" : "2014-06-11", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-06-11T15:53:26.9521977Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-06-04", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Abortion"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, with reference to the Answer of 7 May 2014, Official Report, column 230W, on abortion, whether his Department has formed a view as to when the Royal college of Gynaecologists and Obstetricians publication, The Care of Women Requesting Induced Abortion, should be updated in order to take into account new research; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1594", "label" : {"_value" : "Biography information for Mark Durkan"}
      }
      , "tablingMemberConstituency" : {"_value" : "Foyle"}
      , "tablingMemberPrinted" : [{"_value" : "Mark Durkan"}
      ], "uin" : "198620"}
    ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&answer.answeringMemberConstituency=Battersea&answer.answeringMember.label=Biography+information+for+Jane+Ellison&max-answer.dateOfAnswer=2014-06-11", "page" : 0, "startIndex" : 1, "totalResults" : 195, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}